- Home
- IBTA vs CRMD Comparison
IBTA vs CRMD Comparison
Compare IBTA & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$6.29
Company Overview
Basic Information| Metric | IBTA | CRMD |
|---|---|---|
| Founded | 2011 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 604.2M | 561.8M |
| IPO Year | 2024 | 2009 |
Fundamental Metrics
Financial Performance| Metric | IBTA | CRMD |
|---|---|---|
| Price | $23.00 | $6.29 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | ★ $28.50 | $14.67 |
| AVG Volume (30 Days) | 348.0K | ★ 1.4M |
| Earning Date | 01-01-0001 | 06-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 780.00 |
| EPS | 0.12 | ★ 2.04 |
| Revenue | ★ $342,389,000.00 | $311,709,000.00 |
| Revenue This Year | $1.09 | $1.10 |
| Revenue Next Year | $10.15 | N/A |
| P/E Ratio | $192.17 | ★ $3.14 |
| Revenue Growth | N/A | ★ 617.03 |
| 52 Week Low | $19.10 | $5.60 |
| 52 Week High | $56.60 | $17.43 |
Technical Indicators
Market Signals| Indicator | IBTA | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 51.79 | 34.77 |
| Support Level | $21.10 | $6.13 |
| Resistance Level | $28.32 | $7.44 |
| Average True Range (ATR) | 1.68 | 0.30 |
| MACD | -0.09 | -0.00 |
| Stochastic Oscillator | 32.01 | 11.79 |
Price Performance
Historical Comparison IBTA
CRMD
About IBTA Ibotta Inc.
Ibotta Inc is a performance marketing platform. It allows CPG brands to deliver digital promotions to consumers through a single, convenient network called the Ibotta Performance Network (IPN).
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.